(S)-N-(1-Deutero-1-(3-Chloro-5-Fluoro-2-((2-Methyl-4-(1-Methyl-1H-1,2,4-Triazol-5-Yl)Quinolin-8-Yloxy)Methyl)Phenyl)Ethyl)-2-(Difluoromethoxy)Acetamide

2 trials 1 recruiting

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

1 Recruiting

1 Completed trials

1 Sponsors

14 Countries

Phase II/III

Phase II

Phase II/III: 1 Phase II: 1

Oversight events:

1 corrective measure across 1 trial

View oversight register →

Indications tested

Hereditary angioedema 1

Sponsors using this IMP

Pharvaris Netherlands B.V. 2

All trials

2 total

An extension phase 2/3 study to test the safety of long term administration of oral PHA-022121 for acute treatment of angioedema attacks in … Recruiting

2023-505766-28-00 Phase II/III 14 countries Pharvaris Netherlands B.V.
A blinded, placebo-controlled and randomized phase 2 study to test different doses of oral PHA-022121 for prophylaxis of angioedema attacks … Ended

2023-505549-18-00 Phase II 6 countries Pharvaris Netherlands B.V.

Showing 1–2 of 2 trials

← All drugs A–Z